The oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow Alzheimer's disease progression in the highly awaited EVOKE phase III trials, Novo Nordisk announced Monday. The company shared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback